KPV Peptide: Benefits vs Evidence, Side Effects & Legality
KPV: the quick answer
- What it is
- KPV is a tripeptide: three amino acids (lysine, proline and valine) that form the tail end of the natural hormone alpha-MSH. It is researched for anti-inflammatory effects in the gut and the skin.
- Evidence level
- Laboratory (cell) and animal studies, mainly rodent colitis models. No completed human clinical trial of KPV has been published.
- Status
- Not an approved medicine in the US or UK. In the US, HHS has said it does not intend to take enforcement action against state-licensed pharmacies that compound KPV on its own, for topical or oral use, on a patient-specific prescription. This is interim enforcement discretion, not FDA approval.
This page is informational and does not diagnose, prescribe, or recommend therapies.
What is KPV?
KPV is one of the smallest molecules on this site: a chain of just three amino acids, lysine, proline and valine, whose one-letter codes (K, P and V) give it its name. Those three amino acids are the C-terminal end, the last three links, of alpha-melanocyte-stimulating hormone (alpha-MSH), a hormone the body makes itself. KPV is of research interest because it appears to carry much of the parent hormone's anti-inflammatory signal without the hormone's pigmentation effects.
Research on KPV centers on inflammatory bowel conditions and on skin inflammation. In rodent colitis models (the DSS and TNBS models, two laboratory methods of inducing colitis) KPV reduced inflammation. Unusually for a peptide, it also appears to survive being given by mouth: in those studies it entered intestinal cells through a transporter called PepT1. Most peptides are digested before they can do anything, which is why that finding drew attention.
The proposed mechanism is direct anti-inflammatory signalling. KPV enters cells and interferes with the activation of NF-κB, a switch inside cells that turns on inflammatory signalling, reducing production of inflammatory cytokines such as TNF-alpha and IL-6. It apparently does this without needing the melanocortin receptors its parent hormone uses. All of this is preclinical: it describes what happens in cells and in rodents, not what happens in people.
KPV became news in 2026 for regulatory rather than scientific reasons (the US timeline is further down this page). The change affected who may make it in the US. It did not change what is known about whether it works in people.
What KPV is used for
- Gut-health protocols, where KPV is positioned for inflammatory bowel support, alongside or instead of BPC-157.
- Skin and wound contexts, on the strength of the preclinical anti-inflammatory findings.
- Multi-peptide blends sold online that combine KPV with peptides such as GHK-Cu, BPC-157 and TB-500. A blend has more than one active ingredient, so it falls outside the US policy.
- US compounding on prescription, topical or oral only, within the interim HHS policy (see legal status below).
Claimed benefits vs what the evidence shows
The claims people most often search for about KPV, set against the research. The evidence level names the kind of study a claim rests on: cell (laboratory) studies, animal studies, human studies, or none. Educational only, not medical advice.
Overall: Preclinical only: rodent colitis models (DSS and TNBS) show reduced inflammation, with oral activity via the PepT1 transporter and NF-κB damping in cell studies. No completed human clinical trial of KPV has been published, and we found no registered human trial of KPV (last reviewed October 30, 2026). Human data: None completed. Cell and animal evidence only.
| Claim | Evidence level | What the evidence shows |
|---|---|---|
| “Reduces gut inflammation in colitis and IBD” | Animal | Rodent colitis models (DSS and TNBS) showed reduced inflammation. No completed human trial of KPV has been published for colitis or any other inflammatory bowel condition, so its effect in people with these diseases is unknown. For a serious, diagnosed disease, that gap is the whole story. |
| “Works when taken by mouth, unlike most peptides” | Cell and animal | In rodent and cell studies KPV entered intestinal cells through the PepT1 transporter and remained active. That makes it scientifically interesting. It does not show that any capsule sold for people delivers active KPV, and under the US policy an oral form needs documentation of adequate bioavailability. |
| “Calms skin inflammation and helps wounds heal” | Cell (extrapolated from gut findings) | Interest in skin and wounds rests on the same preclinical anti-inflammatory findings. No completed human trial of KPV has been published, on skin or anything else. |
| “A whole-body anti-inflammatory” | Cell | The NF-κB and cytokine findings (lower TNF-alpha and IL-6) come from cell studies. A mechanism seen in cells is not evidence of a body-wide effect in people. |
| “The FDA just approved KPV for compounding” | Not evidence | In October 2026 HHS announced an interim enforcement-discretion policy for 503A compounding of KPV, for topical and oral use only and as a single ingredient. HHS says it does not grant FDA approval or establish safety and effectiveness. It governs who may compound KPV, not whether it works. |
| “Harmless, because it is a fragment of a natural hormone” | None | Its small size and natural-fragment origin are often cited as reassurance, but neither substitutes for human study. With no completed trials there is no adverse-event profile and no long-term data. |
Reading the KPV evidence: what cell and animal results can and cannot tell you
Almost everything written about KPV traces back to two kinds of study. Each answers a different question, and neither answers the one most readers are asking, which is whether KPV helps a person.
Cell studies show a mechanism. In laboratory cultures KPV entered cells, including intestinal cells through the PepT1 transporter, and interfered with NF-κB activation, lowering inflammatory cytokines such as TNF-alpha and IL-6. That explains why KPV might reduce inflammation. It cannot show that it does so in a living body, at what amount, or with what side effects.
Animal studies show an effect in a model. In the DSS and TNBS rodent colitis models, KPV reduced inflammation, including when given by mouth. That is a stronger signal than a cell result, because it happened in a living animal. It is still a model of colitis in rodents, not inflammatory bowel disease in people, and the step from elegant rodent mechanism to proven human benefit is the step KPV has not yet taken.
Human studies are the missing level. No completed human clinical trial of KPV has been published, and we found no registered human trial of KPV (last reviewed October 30, 2026). That means no human data on whether it reduces gut or skin inflammation, no established dose, and no adverse-event profile.
What would change the picture is a registered, completed and published human trial of KPV for a defined condition. Until then, the honest description of KPV is a promising preclinical anti-inflammatory peptide, not a treatment.
KPV vs BPC-157 for gut health
KPV and BPC-157 are the two peptides most often discussed for gut health, and they are sometimes sold together in blends. They are different molecules with different origins, and the US policy treats them differently.
- Origin: KPV is the three-amino-acid tail of the hormone alpha-MSH. BPC-157 is a 15-amino-acid sequence derived from a protein found in human gastric juice.
- What is studied: KPV for anti-inflammatory signalling in the gut and skin. BPC-157 for tissue and gut repair, including tendon, ligament and blood-vessel effects.
- Evidence level: both rest on cell and animal research. Neither has robust human trial evidence for gut conditions.
- US policy route: KPV is covered for topical or oral use only. BPC-157 is covered by subcutaneous or intramuscular injection, by mouth or on the skin. Each is covered only on its own, so a product containing both is outside the policy.
- Sport: KPV is not named on the WADA list, but as a substance approved nowhere it would generally fall under S0 (non-approved substances, prohibited at all times). BPC-157 falls under WADA's S0 (non-approved substances) category and is prohibited at all times.
KPV side effects and risks
What is known
No side-effect profile has been established for KPV in people. A list of side effects needs controlled human data, and no human trial of KPV has been completed, so any list you see online cannot come from one.
What is not known
With no completed trials there is no established dosing, no adverse-event profile and no long-term safety data. Its small size and its origin as a fragment of a natural hormone are reassuring stories, not safety evidence.
Product quality and gray-market vials
Most KPV sold online is research-chemical supply, labeled for research use, whose identity and purity are unverified: what is in the vial or capsule, and how much, is not independently checked. A product compounded on prescription under the US policy at least carries quality controls; a 'research use only' product meets none of the policy's conditions. The policy's conditions are under legal status.
Who should take particular care
- Anyone with diagnosed or suspected inflammatory bowel disease. It is serious, specialist territory: gut symptoms serious enough to send you researching KPV need diagnosis first, and care from a gastroenterologist.
- Tested athletes. KPV is not named on the WADA list, but as a substance approved nowhere it would generally fall under S0 (non-approved substances, prohibited at all times). Check with your anti-doping organization first.
- Anyone offered injectable KPV, or KPV in a blend. Neither is covered by the US policy.
KPV dosage: why this page gives no dose
There is no approved dose of KPV anywhere: no regulator has approved it, and no completed human trial has tested a dose. Under the US policy a compounded KPV product is made for one named patient on a prescription, so the amount, the form (topical or oral) and the schedule are set by the prescriber.
Figures quoted on forums and research-chemical sites are not drawn from completed human trials, because there are none.
Peptide Clinic Finder does not give doses, and this page has no dosing chart. If you have been prescribed it, the amount, form and schedule are the prescriber's and the pharmacy's instructions, not a figure from a website.
- peptide calculator: There is no KPV-specific calculator on this site. The general peptide calculator does arithmetic only (concentration, volume and syringe units) for a reconstituted vial, and the US policy covers KPV for topical or oral use, not injection.
Is KPV legal? US, UK and sport status
United States
Not FDA-approved. Under the HHS interim policy announced on October 28, 2026 and published in the Federal Register on October 30, 2026, state-licensed pharmacies, federal facilities and licensed physicians may compound KPV acetate for an individual prescription, as the only active ingredient, for topical and oral use only (not injection), if the policy's conditions are met; an oral form needs documentation of adequate bioavailability. Interim enforcement discretion, not approval, and it implies no proven benefit (checked October 30, 2026).
Source: FDA: Drugs@FDA (openFDA) — no matching approved product · United States · Status verified August 31, 2026
Source: HHS: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Docket HHS-OASH-2026-0496), Federal Register public inspection copy · United States · Published October 30, 2026
What the policy requires: for KPV, the covered form is KPV acetate, for topical or oral use only, not by injection; an oral form needs documentation of adequate bioavailability. The other conditions in Appendix B are the same for all six peptides it lists: a licensed clinician prescribes it for an individual patient; a state-licensed pharmacy compounds it from bulk ingredient made by an FDA-registered, CGMP manufacturer with a certificate of analysis; the product contains no other active ingredient; the label says it is a compounded drug product, not for resale; and serious adverse events are reported to FDA's MedWatch and to the states involved. The policy does not cover 503B outsourcing facilities, “research use only” products or dietary supplements. Our guide to the October 2026 US peptide policy sets out each condition and its source.
Source: HHS: 503A peptide enforcement discretion policy, Appendix B: conditions and covered routes of administration · United States · Published October 28, 2026 · Accessed October 30, 2026
The same interim policy covers five other peptides, each only on its own and by its own route: TB-500 peptide (covered by subcutaneous or intramuscular injection), Semax peptide (covered for intranasal use only), Epitalon peptide (covered by subcutaneous or intramuscular injection, dispensed in intermittent courses), BPC-157 peptide (covered by subcutaneous or intramuscular injection, by mouth or on the skin) and MOTS-c peptide (covered by subcutaneous or intramuscular injection).
United Kingdom
Not a licensed UK medicine. No current UK marketing authorization was found for KPV in the MHRA Products register as of August 31, 2026. The HHS policy is US only and changes nothing in the UK or Ireland.
Source: MHRA: MHRA Products register · United Kingdom · Status verified August 31, 2026
Sport (anti-doping)
Not named on the WADA prohibited list, but as a substance approved nowhere it would generally fall under S0 (non-approved substances, prohibited at all times). Tested athletes should verify with their anti-doping organization.
Source: WADA: International Standard — Prohibited List 2026 · International (WADA Code signatories) · In force January 1, 2026
Last reviewed October 30, 2026. Regulatory status can change. Always confirm the current position with a qualified clinician.
KPV in 2026: the US timeline
- July 2026: the FDA's Pharmacy Compounding Advisory Committee voted to recommend KPV for the 503A bulks list.
- October 28, 2026: the HHS Office of the Secretary announced an interim enforcement-discretion policy for 503A compounding of six peptides, KPV among them, for topical and oral use only.
- October 30, 2026: the policy was published in the Federal Register (Docket No. HHS-OASH-2026-0496). Written comments are accepted for two weeks after publication, and HHS says it may revisit the policy.
Questions to ask a prescriber or clinic about KPV
- No completed human trials of KPV exist. What is the basis for recommending it for my condition?
- If I have an inflammatory bowel condition, is a gastroenterologist involved in my care?
- Is your KPV from a licensed compounding pharmacy, and what does its quality documentation show?
What a credible provider tells you
- A credible provider should state plainly that no completed human trials of KPV exist.
- Expect accurate framing of the 2026 compounding developments: the interim HHS policy is enforcement discretion, covers topical and oral KPV only, and is not approval.
- Gut-condition claims deserve particular care, as inflammatory bowel disease is serious, diagnosed, specialist territory.
Red flags
- Presenting KPV as a proven treatment for IBD, colitis, or any diagnosed condition. No human trial supports that.
- Framing the 2026 HHS compounding policy, or the earlier advisory-committee vote, as FDA approval or as evidence of efficacy.
- Encouraging people to self-treat serious gut symptoms that need diagnosis first.
KPV cost and US availability
Most KPV sold online is research-chemical supply with unverified identity and purity. Under the interim HHS policy announced on October 28, 2026, a US state-licensed pharmacy may compound topical or oral KPV on prescription, which at least carries quality controls, and bmiMD, a provider we list, now sells KPV on its own as a topical cream on prescription (checked November 18, 2026); the human-evidence gap is unchanged. See the peptide therapy cost guide. For what the October 2026 HHS policy changed for the six peptides it covers, and whether any provider we list sells each one, read our guide to the October 2026 US peptide policy.
Frequently asked questions about KPV
What is KPV?
A tripeptide — lysine-proline-valine — that forms the anti-inflammatory tail of the natural hormone alpha-MSH. It is studied mainly for gut and skin inflammation, with all completed evidence coming from cell and animal research.
What is KPV peptide used for?
KPV is researched for inflammation in the gut, such as colitis, and in the skin. Providers who reference it position it for gut-health or skin support, and some multi-peptide blends include it. Those uses rest on cell and animal studies; no completed human trial of KPV has been published.
Does KPV work?
In people, nobody knows yet. Rodent colitis models and cell studies show anti-inflammatory effects, including when given by mouth, but no completed human trial of KPV has been published, and we found no registered human trial of KPV (last reviewed October 30, 2026), so there is no evidence either way on whether it helps people.
Does KPV work for gut problems like colitis or IBD?
Rodent colitis models show reduced inflammation, including with oral dosing — a genuinely interesting result. But no completed human trial of KPV has been published, so its effect in people with real digestive disease is unknown. Anyone with those symptoms should be under a gastroenterologist's care.
Is KPV legal in the US?
Within limits. Under an interim HHS policy announced on October 28, 2026 (published in the Federal Register on October 30), HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities and licensed physicians that compound KPV acetate, as the only active ingredient, for topical or oral use on an individual prescription, if the policy's conditions are met; an oral form needs documentation of adequate bioavailability. That is not FDA approval and HHS may revisit it. Injectable KPV, blends that contain KPV and 'research use only' products are outside it. bmiMD, a provider we list, sells KPV on its own as a topical cream on prescription (checked November 18, 2026).
Is KPV FDA approved?
No. No FDA-approved KPV product exists. HHS says its interim compounding policy does not grant FDA approval or establish safety and effectiveness; it governs who may compound KPV, not whether it works.
Is KPV safe?
Unknown in the formal sense: with no completed human trials there is no established dosing, adverse-event profile, or long-term safety data. Its small size and natural-fragment origin are often cited as reassurance, but neither substitutes for human study.
Is KPV legal in the UK?
KPV is not a licensed medicine in the UK: no current UK marketing authorization was found in the MHRA Products register as of August 31, 2026. The US compounding policy does not apply in the UK or Ireland.
Is KPV banned in sport?
KPV is not named on the WADA list, but as a substance approved nowhere it would generally fall under S0 (non-approved substances, prohibited at all times). Tested athletes should verify with their anti-doping organization before using it.
How is KPV different from BPC-157?
Both are discussed for gut health, and both rest on preclinical evidence. KPV is three amino acids from the tail of the hormone alpha-MSH, studied for anti-inflammatory signalling; BPC-157 is a 15-amino-acid sequence derived from a protein in gastric juice, studied for tissue and gut repair. Under the US policy KPV is covered for topical or oral use only, BPC-157 by subcutaneous or intramuscular injection, by mouth or on the skin, each only on its own.
Does Peptide Clinic Finder sell or recommend KPV?
No. Peptide Clinic Finder is an informational directory. We do not sell KPV, provide medical advice, or recommend its use — we explain the real evidence and regulatory state so you can make informed decisions with a licensed clinician.
Next step
Compare Providers and Next Steps
If you are considering this treatment, compare providers, review your options, and choose the path that best fits your goals and preferred level of care.
Related KPV pages
Move from peptide research into clinic comparisons, guides, and matching.
Not sure whether local clinics or online options are the better fit? compare providers or use our matching tool to find the right next step. If you want a broader market view first, find a peptide clinic near you.
Clinics offering KPV
Explore clinics by city
What to do next
Move from treatment research into provider comparison by choosing the next step that fits your buying journey. Some users want to compare programs first, while others want a faster route into matched options or local clinic discovery.
Next step
Explore suitable clinics
Move from peptide research into real provider comparison by checking city pages, cost context, and related treatment comparisons. Clinics vary more by oversight and program structure than by peptide name alone.
Related goals
Related conditions
Related comparisons
Browse city pages
For clinics
Are you a clinic?
Get featured on this page and reach patients actively looking for peptide therapy, GLP-1 treatments, recovery support, and longevity care.